Total Payments
$392,798
2024 Payments
$65,323
Companies
21
Transactions
315
Medicare Patients
155
Medicare Billing
$16,946
Payment Breakdown by Category
Research$357,321 (91.0%)
Travel$24,501 (6.2%)
Food & Beverage$9,471 (2.4%)
Consulting$1,500 (0.4%)
Education$5.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $357,321 | 55 | 91.0% |
| Travel and Lodging | $24,501 | 73 | 6.2% |
| Food and Beverage | $9,471 | 185 | 2.4% |
| Consulting Fee | $1,500 | 1 | 0.4% |
| Education | $5.26 | 1 | 0.0% |
Payments by Type
Research
$357,321
55 transactions
General
$35,477
260 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $291,545 | 144 | $0 (2024) |
| Eli Lilly Export S.A. Puerto Rico Branch | $87,789 | 13 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $2,070 | 18 | $0 (2021) |
| Medtronic MiniMed, Inc. | $1,547 | 4 | $0 (2019) |
| AbbVie, Inc. | $1,468 | 10 | $0 (2019) |
| SANOFI PASTEUR INC. | $1,330 | 6 | $0 (2017) |
| Novo Nordisk AS | $1,298 | 4 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $1,266 | 21 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $1,115 | 18 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $840.10 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,323 | 28 | Eli Lilly and Company ($48,433) |
| 2023 | $14,187 | 50 | Eli Lilly and Company ($13,743) |
| 2022 | $78,190 | 28 | Eli Lilly and Company ($76,445) |
| 2021 | $26,656 | 11 | Eli Lilly and Company ($26,536) |
| 2020 | $28,977 | 40 | Eli Lilly and Company ($28,789) |
| 2019 | $45,871 | 53 | Eli Lilly and Company ($38,933) |
| 2018 | $112,484 | 55 | Eli Lilly Export S.A. Puerto Rico Branch ($68,438) |
| 2017 | $21,109 | 50 | Eli Lilly and Company ($17,621) |
All Payment Transactions
315 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $29,443.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $9,088.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/12/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $7,498.00 | Research |
| 09/03/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $17,142.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | ||||||
| 08/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $121.20 | General |
| Category: Endocrinology | ||||||
| 08/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Endocrinology | ||||||
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $237.46 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $103.58 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $102.02 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $65.92 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $65.92 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $32.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $28.24 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $28.24 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $15.00 | General |
| 05/26/2024 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological), TZIELD, TOUJEO | Food and Beverage | In-kind items and services | $142.94 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $382.12 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $50.93 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $31.22 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1.52 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $0.93 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $0.90 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly Export S.A. Puerto Rico Branch | $63,152 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $52,224 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $34,414 | 3 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $33,454 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $29,883 | 2 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $20,189 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $19,688 | 3 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $18,801 | 3 |
| A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | Eli Lilly and Company | $17,142 | 1 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $11,878 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly Export S.A. Puerto Rico Branch | $9,088 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $7,940 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly Export S.A. Puerto Rico Branch | $7,565 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $5,782 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $5,235 | 1 |
| THE EFFECT OF DULAGLUTIDE ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES - RESEARCHING CARDIOVASCULAR EVENTS WITH A WEEKLY INCRETIN IN DIABETES - REWIND | Eli Lilly and Company | $4,452 | 2 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION | Eli Lilly and Company | $2,689 | 2 |
| Efficacy, Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection | SANOFI PASTEUR INC. | $1,330 | 6 |
| M16-100 | AbbVie, Inc. | $1,327 | 8 |
| NN9535-4352 | Novo Nordisk AS | $1,298 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $851.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $582.00 | 1 |
| A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | Eli Lilly and Company | $562.68 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $298.02 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 21 | 31 | $6,200 | $2,562 |
| 2021 | 2 | 50 | 79 | $14,450 | $6,719 |
| 2020 | 4 | 84 | 120 | $17,135 | $7,664 |
Total Patients
155
Total Services
230
Medicare Billing
$16,946
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 31 | $6,200 | $2,562 | 41.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 61 | $12,200 | $5,383 | 44.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 18 | $2,250 | $1,336 | 59.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 57 | $9,420 | $4,024 | 42.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $3,090 | $1,794 | 58.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 24 | $2,900 | $1,088 | 37.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 19 | 27 | $1,725 | $759.20 | 44.0% |
About Angel Comulada
Angel Comulada is a Endocrinology, Diabetes & Metabolism healthcare provider based in Bayamon, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669559803.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Angel Comulada has received a total of $392,798 in payments from pharmaceutical and medical device companies, with $65,323 received in 2024. These payments were reported across 315 transactions from 21 companies. The most common payment nature is "" ($357,321).
As a Medicare-enrolled provider, Comulada has provided services to 155 Medicare beneficiaries, totaling 230 services with total Medicare billing of $16,946. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Bayamon, PR
- Active Since 11/01/2006
- Last Updated 02/03/2016
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669559803
Products in Payments
- TRULICITY (Drug) $4,911
- Minimed 670G System (Device) $2,338
- JANUVIA (Drug) $1,879
- Ozempic (Drug) $1,373
- NO PRODUCT DISCUSSED (Drug) $1,330
- Androgel (Drug) $1,327
- JARDIANCE (Drug) $940.10
- XARELTO (Drug) $747.74
- INVOKANA (Drug) $445.77
- SOLIQUA 100/33 (Biological) $409.64
- FARXIGA (Drug) $224.37
- TOUJEO (Biological) $207.67
- STEGLATRO (Drug) $190.91
- ELIQUIS (Drug) $180.52
- Dexcom G6 Transmitter (Medical Supply) $146.67
- Synthroid (Drug) $141.72
- DEXCOM G7 GSS (161) (Medical Supply) $121.20
- SOLIQUA (Drug) $105.68
- DEXCOM CGM (Device) $101.69
- FreeStyle Lite system (Device) $101.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Bayamon
Gloria Vega Carattini, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $42,216
Endocrinology, Diabetes & Metabolism $42,216
Jean Pujals Kury, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $39,457
Endocrinology, Diabetes & Metabolism $39,457
Yanira Marrero Mcfaline, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $20,284
Endocrinology, Diabetes & Metabolism $20,284
Dr. Mariela Nieves-Rodriguez, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $7,167
Endocrinology, Diabetes & Metabolism $7,167
Giovanna Rodriguez Figueroa, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,567
Endocrinology, Diabetes & Metabolism $2,567
Amelia Guzman-Bicchi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1,612
Endocrinology, Diabetes & Metabolism $1,612